DATE
Biopharma Layoff Tracker 2024: CureVac, Takeda, Aerovate and More Cut Staff
Biopharma, Layoffs, 2024, CureVac, Takeda, Aerovate, Job Cuts, Industry Trends
Eisai Seeks FDA Approval for Monthly IV Dosing of LEQEMBI for Alzheimer’s Disease Treatment
LEQEMBI, Eisai, FDA, Alzheimer’s disease, monthly IV dosing, subcutaneous autoinjector, lecanemab-irmb, Biogen
ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment
ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW
Rapport, a J&J Neuroscience Spinout, Prepares for Summer IPO as the First Biotech of the Season
Rapport, IPO, J&J, neuroscience, biotech, summer plans, Third Rock.
AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory
AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.
Merck KGaA Remains Optimistic About CDMO Business Prospects Amidst Q1 Downturn
Merck KGaA, CDMO, first-quarter, slump, optimism, business prospects, pharmaceutical industry.
Ascendis Hormone Replacement Therapy Faces Setback with FDA Review Extension
Ascendis Pharma, hormone replacement therapy, FDA review, delay, three-month extension.
Extended FDA Review Timeline for Ascendis’ Hormone Therapy
Ascendis Pharma, hormone therapy, FDA review, delay, 3 months extension.
FDA Imposes Three-Month Delay on Ascendis’ Hypoparathyroidism Treatment
Ascendis Pharma, hypoparathyroidism, FDA, drug approval, delay, three-month setback, regulatory hurdle, treatment, endocrine disorder.
Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis
Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.